BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. As a small, R&D-driven company, we identify areas where there is a strong need but a significant technical hurdle, and then we develop a solution. Transcreener® Biochemical Assay Technology: Our proprietary Transcreener® HTS Platform was developed to move more new targets into HTS more rapidly, and to streamline selectivity profiling within a target family. It relies on homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, GDP, AMP and GMP, that are formed by thousands of cellular enzymes. Among these are group transferase families, such as kinases and glycosyltransferases, that catalyze the covalent regulatory reactions that are central to cell signaling. Each Transcreener Assay provides a generic detection method for multiple enzyme families. This means that you can focus on evaluating new therapeutic strategies and optimizing lead molecules rather than on time-consuming assay development for individual targets. The platform has been rapidly validated and adopted by pharmaceutical and biotechnology screening labs around the world.